Compendium of Cancer Genome Aberrations

T-large granular lymphocytic leukaemia

Revision as of 17:35, 6 September 2024 by Bailey.Glen (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Haematolymphoid Tumours (WHO Classification, 5th ed.)

editContent Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification
This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:T-cell Large Granular Lymphocytic Leukemia.

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)

Primary Author(s)*

  • Michelle Don, MD, MS

WHO Classification of Disease

Structure Disease
Book Haematolymphoid Tumours (5th ed.)
Category T-cell and NK-cell lymphoid proliferations and lymphomas
Family Mature T-cell and NK-cell neoplasms
Type Mature T-cell and NK-cell leukaemias
Subtype(s) T-large granular lymphocytic leukaemia

Definition / Description of Disease

  • Increased peripheral blood large granular lymphocytes (LGLs) for >6 months without a identifiable cause
  • Chronic and often indolent T-cell proliferation


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[1]

Synonyms / Terminology

  • T-cell large granular lymphocytic leukemia

Epidemiology / Prevalence

  • 2-3% of mature small lymphocytic leukemias
  • Male:Female ~ 1:1
  • Most commonly occurs between ages 45-75 years old


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[1]

Clinical Features

Put your text here and fill in the table (Instruction: Can include references in the table. Do not delete table.)

Signs and Symptoms EXAMPLE: Asymptomatic (incidental finding on complete blood counts)

EXAMPLE: B-symptoms (weight loss, fever, night sweats)

EXAMPLE: Fatigue

EXAMPLE: Lymphadenopathy (uncommon)

Laboratory Findings EXAMPLE: Cytopenias

EXAMPLE: Lymphocytosis (low level)


editv4:Clinical Features
The content below was from the old template. Please incorporate above.


  • Severe neutropenia
  • Lymphocyte count usually 2-20x109/L
  • Has been reported to occur with:
    • Severe red cell hypoplasia
    • Rheumatoid arthritis
    • Low grade B-cell malignancies


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[1]

Sites of Involvement

  • Peripheral blood and bone marrow
  • Spleen - infiltration and expansion of red pulp
  • Liver
  • Skin (rare)
  • Lymph nodes (exceptional)


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[1]

Morphologic Features

Large granular lymphocytes

  • Moderate to abundant cytoplasm
  • Fine or course azurophilic granules

Immunophenotype

Finding Marker
Positive CD8, CD2, CD3, CD16, CD57, αβ (alpha-beta) TCR

Cytotoxic effector proteins: TIA1, Granzyme B, Granzyme M

Negative CD4, CD5, CD7
Please note:
  • Cases of CD4+ LGL leukemia has been described[2]
  • Cases of CD4-/CD8-, γδ (gamma-delta) T-LGL leukemia has also been described (<5% of cases)[3]


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[1]

Chromosomal Rearrangements (Gene Fusions)

Put your text here and fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: t(9;22)(q34;q11.2) EXAMPLE: 3'ABL1 / 5'BCR EXAMPLE: der(22) EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add reference)

Yes No Yes EXAMPLE:

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).


editv4:Chromosomal Rearrangements (Gene Fusions)
The content below was from the old template. Please incorporate above.
  • No known chromosomal rearrangements


editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).
Please incorporate this section into the relevant tables found in:
  • Chromosomal Rearrangements (Gene Fusions)
  • Individual Region Genomic Gain/Loss/LOH
  • Characteristic Chromosomal Patterns
  • Gene Mutations (SNV/INDEL)
  • There are no FDA approved targeted therapies for T-LGL
  • STAT3 mutations can be used to follow-up, in response to treatment[4]
    • Take caution as STAT mutations are not specific to T-LGL and can be seen in other T-cell lymphomas
  • STAT3 mutation, Y640F, has a predicted response to initial therapy with methotrexate[5]
  • Bortezomib is considered due to NF-κB constitutive activity in T-LGL leukemia[6]

Individual Region Genomic Gain / Loss / LOH

Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.)

Chr # Gain / Loss / Amp / LOH Minimal Region Genomic Coordinates [Genome Build] Minimal Region Cytoband Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE:

7

EXAMPLE: Loss EXAMPLE:

chr7:1- 159,335,973 [hg38]

EXAMPLE:

chr7

Yes Yes No EXAMPLE:

Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).

EXAMPLE:

8

EXAMPLE: Gain EXAMPLE:

chr8:1-145,138,636 [hg38]

EXAMPLE:

chr8

No No No EXAMPLE:

Common recurrent secondary finding for t(8;21) (add reference).

editv4:Genomic Gain/Loss/LOH
The content below was from the old template. Please incorporate above.
  • No known recurrent copy number gain/loss/LOH, chromosomal abnormalities have been reported in few cases[7]

Characteristic Chromosomal Patterns

Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.)

Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE:

Co-deletion of 1p and 18q

Yes No No EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

editv4:Characteristic Chromosomal Aberrations / Patterns
The content below was from the old template. Please incorporate above.
  • No characteristic chromosomal aberrations have been identified
  • Unique cytogenetic findings include: (reported in one case report of γδ variant T-cell LGL)[8]
    • Interstitial deletion of 3p21.31, monosomy X, trisomy 5, monosomy 21, and CN‐LOH located at 17q[8]

Gene Mutations (SNV / INDEL)

Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well as either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable. Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Do not delete table.)

Gene; Genetic Alteration Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) Prevalence (COSMIC / TCGA / Other) Concomitant Mutations Mutually Exclusive Mutations Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: TP53; Variable LOF mutations

EXAMPLE:

EGFR; Exon 20 mutations

EXAMPLE: BRAF; Activating mutations

EXAMPLE: TSG EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add Reference)

EXAMPLE: IDH1 R123H EXAMPLE: EGFR amplification EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).


Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


editv4:Gene Mutations (SNV/INDEL)
The content below was from the old template. Please incorporate above.

Somatic activating STAT3 and STAT5b mutations are the most common SNVs in T-LGL.

Gene* Mutation Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) Prevalence Additional information
STAT3
  • Src-like homologue 2 (SH2) domain of STAT3
  • Most frequently affecting codons Y640 or D661[1]
    • Also affecting:
  • Causing constitutive phosphorylation of the mutated proteins, and increased the transcriptional activity of STAT3 in vitro[10][11]
 GOF 40-70%[11]
  • 17% of patients with STAT3 mutations, had multiple mutations in the STAT3 gene, solely in cytotoxic CD8+ or NK cells.[4]
  • Take caution as STAT3 mutation can also be seen in other T-cell lymphomas including hepatosplenic T-cell lymphoma[12]
STAT5B
  • Src-like homologue 2 (SH2) domain of STAT5
  • Including: N642H mutation (associated with more aggressive disease)[13][14]
  • Causing constitutive phosphorylation of the mutated proteins, and increased the transcriptional activity of STAT5B in vitro[10][11]
 GOF 2%[13]
TNFAIP3
  • Somatic mutations[9]
    • Y353X
    • K354K
    • Q741Q
    • E630X
    • A717T
    • F127C
 LOF (Nonsense mutations)[9] Identified in 3/39 patients[9]
  • In one study three of four of the patients with non‐synonymous TNFAIP3 alterations also harbored a STAT3 mutation (p  = 0.004)[9]
  • TNFAIP3 itself is a NF‐κB target gene[15]

*More comprehensive listing of specific mutations in these genes can be found elsewhere (COSMIC, cBioPortal)

Epigenomic Alterations

  • Epigenetic inactivation of JAK/STAT pathway inhibitors
    • SOCS3 has a crucial role in regulating STAT3 activation[16]
    • An epigenetic inhibition mechanism to SOCS3 gene is hypothesized[16]
    • KIR3DL1 has been shown to be down-modulated by hypermethylation of the promoter[16]


Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Can include references in the table. Do not delete table.)

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
EXAMPLE: BRAF and MAP2K1; Activating mutations EXAMPLE: MAPK signaling EXAMPLE: Increased cell growth and proliferation
EXAMPLE: CDKN2A; Inactivating mutations EXAMPLE: Cell cycle regulation EXAMPLE: Unregulated cell division
EXAMPLE:  KMT2C and ARID1A; Inactivating mutations EXAMPLE:  Histone modification, chromatin remodeling EXAMPLE:  Abnormal gene expression program
editv4:Genes and Main Pathways Involved
The content below was from the old template. Please incorporate above.
  • JAK/STAT[7]
    • Constitutive activation
  • NK-κB[7]
    • Activation of this pathway
    • Preventing apoptosis
  • T-LGL's express high levels of FAS and FASL[7]
    • Resistant to FAS mediated apoptosis
    • Leading to activation of prosurvival pathways
    • Postulated to lead to neutropenia seen in these patients.
  • RAS/RAF1/MEK1/ERK [7]
    • Overactive RAS
    • Constitutive activation of RAS and ERK
  • PI3K/AKT[7]
    • Dysregulation
    • Contributing to apoptosis inhibition

Genetic Diagnostic Testing Methods

  • Morphologic assessment, flow cytometry and immunohistochemistry
  • PCR to assess for clonality, T-cell receptor (TCR) gene rearrangements
    • TCR gamma (TCRG) gene is rearranged in all cases, regardless of the type of TCR expressed, thus proves clonality[1]
      • Can be helpful in differentiating a reactive lymphocytosis from clonal T-LGL's
    • NK LGL proliferations do not express TCR, making assessment of clonality difficult[7]
      • Expression of activating isoforms of killer immunoglobulin-like receptors (KIR) can be used as a surrogate marker of clonality in NK LGL[7]

Familial Forms

  • No known familiar forms as of yet.

Additional Information

  • N/A

Links

References

(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Chan W.C., et al., (2017). T-cell large granular lymphocytic leukemia, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p 348-350.
  2. ↑ Lima M, Almeida J, dos Anjos Teixeira M, del Carmen Alguero M, Santos AH, Balanzategui A, Queirós ML, Bárcena P, Izarra A, Fonseca S, Bueno C. TCRαβ+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder. The American journal of pathology. 2003 Aug 1;163(2):763-71.
  3. ↑ Chen YH, Chadburn A, Evens AM, Winter JN, Gordon LI, Chenn A, Goolsby C, Peterson L. Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4–/CD8–γδ T-cell large granular lymphocytic leukemia. American journal of clinical pathology. 2011 Aug 1;136(2):289-99.
  4. ↑ 4.0 4.1 Rajala HL, Olson T, Clemente MJ, Lagström S, Ellonen P, Lundan T, Hamm DE, Zaman SA, Marti JM, Andersson EI, Jerez A. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. haematologica. 2015 Jan 1;100(1):91-9.
  5. ↑ Loughran TP, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia. 2015 Apr;29(4):886-94.
  6. ↑ Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer cell. 2012 Nov 13;22(5):645-55.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 Lamy T, Moignet A, Loughran TP. LGL leukemia: from pathogenesis to treatment. Blood. 2017 Mar 2;129(9):1082-94.
  8. ↑ 8.0 8.1 Zhang L, Ramchandren R, Papenhausen P, Loughran TP, Sokol L. Transformed aggressive γδ‐variant T‐cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11. 2q25. 3 and additional aberrations. European journal of haematology. 2014 Sep;93(3):260-4.
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 Johansson P, Bergmann A, Rahmann S, Wohlers I, Scholtysik R, Przekopowitz M, Seifert M, Tschurtschenthaler G, Webersinke G, Jäger U, Siebert R. Recurrent alterations of TNFAIP 3 (A 20) in T‐cell large granular lymphocytic leukemia. International journal of cancer. 2016 Jan 1;138(1):121-4.
  10. ↑ 10.0 10.1 Jerez A, Clemente MJ, Makishima H, Koskela H, LeBlanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood, The Journal of the American Society of Hematology. 2012 Oct 11;120(15):3048-57.
  11. ↑ 11.0 11.1 11.2 Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM. Somatic STAT3 mutations in large granular lymphocytic leukemia. New England Journal of Medicine. 2012 May 17;366(20):1905-13.
  12. ↑ 12.0 12.1 Yabe M, Medeiros LJ, Wang SA, Tang G, Bueso-Ramos CE, Jorgensen JL, Bhagat G, Chen W, Li S, Young KH, Miranda RN. Distinguishing between hepatosplenic T-cell lymphoma and γδ T-cell large granular lymphocytic leukemia. The American journal of surgical pathology. 2017 Jan 1;41(1):82-93.
  13. ↑ 13.0 13.1 Rajala HL, Eldfors S, Kuusanmäki H, Van Adrichem AJ, Olson T, Lagström S, Andersson EI, Jerez A, Clemente MJ, Yan Y, Zhang D. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood, The Journal of the American Society of Hematology. 2013 May 30;121(22):4541-50.
  14. ↑ 14.0 14.1 Rajala HL, Porkka K, Maciejewski JP, Loughran Jr TP, Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic leukemia—novel STAT3 and STAT5b mutations. Annals of Medicine. 2014 May 1;46(3):114-22.
  15. ↑ Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, Albert R, Loughran TP. Network model of survival signaling in large granular lymphocyte leukemia. Proceedings of the National Academy of Sciences. 2008 Oct 21;105(42):16308-13.
  16. ↑ 16.0 16.1 16.2 Teramo, Antonella; et al. (2013-05-09). "Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia". Blood. 121 (19): 3843–3854, S1. doi:10.1182/blood-2012-07-441378. ISSN 1528-0020. PMID 23515927.

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

*Citation of this Page: “T-large granular lymphocytic leukaemia”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 09/6/2024, https://ccga.io/index.php/HAEM5:T-large_granular_lymphocytic_leukaemia.

Other Sections

Cancer Category


Retrieved from "https://ccga.io/index.php?title=HAEM5:T-large_granular_lymphocytic_leukaemia&oldid=15344"